Dexcom (DXCM) Stock Forecast & Price Target

Compare

4,094 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

DXCM Analyst Ratings

Strong Buy

19 Buy

1 Hold

0 Sell

Based on 20 analysts giving stock ratings to

Dexcom

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

DXCM Stock 12 Month Forecast

Average Price Target

$99.04

▲(16.46%Upside)

Based on 20 Wall Street analysts offering 12 month price targets for Dexcom in the last 3 months. The average price target is $99.04 with a high forecast of $110.00 and a low forecast of $85.00. The average price target represents a 16.46% change from the last price of $85.04.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"65":"$65","92":"$92","119":"$119","78.5":"$78.5","105.5":"$105.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":110,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$110.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":99.04,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$99.04</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":85,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$85.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[65,78.5,92,105.5,119],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2024","6":"Dec<br/>2024","9":"Mar<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.51,87.39384615384616,89.2776923076923,91.16153846153847,93.04538461538462,94.92923076923077,96.81307692307692,98.69692307692308,100.58076923076923,102.46461538461539,104.34846153846154,106.2323076923077,108.11615384615385,{"y":110,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.51,86.55076923076923,87.59153846153846,88.63230769230769,89.67307692307693,90.71384615384616,91.75461538461539,92.79538461538462,93.83615384615385,94.87692307692308,95.9176923076923,96.95846153846155,97.99923076923078,{"y":99.04,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,85.51,85.47076923076924,85.43153846153847,85.3923076923077,85.35307692307693,85.31384615384616,85.27461538461539,85.23538461538462,85.19615384615385,85.15692307692308,85.11769230769231,85.07846153846154,85.03923076923077,{"y":85,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":118.77,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":112.17,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.32,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":69.34,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.35,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.31,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.77,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":86.83,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 38,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":88.37,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 43,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.32,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":70.26,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 48,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":85.51,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 44,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$110.00

Average Price Target$99.04

Lowest Price Target$85.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

TipRanks AITipRanks

Not Ranked

TipRanks

$100

Buy

17.59%

Upside

Reiterated

06/25/25

Dexcom's strong financial performance and strategic expansion into the type 2 diabetes market are significant strengths. However, valuation concerns due to a high P/E ratio and challenges such as declining gross margins and an FDA warning letter impact the overall score. The company's strategic initiatives and management confidence, as reflected in the share repurchase program, provide a balanced outlook.

Steven LichtmanOppenheimer

Oppenheimer

$95

Buy

11.71%

Upside

Reiterated

06/24/25

Oppenheimer Sticks to Its Buy Rating for Dexcom (DXCM)

Larry BiegelsenWells Fargo

Wells Fargo

$98

Buy

15.24%

Upside

Reiterated

06/24/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Dexcom (NASDAQ: DXCM), Select Medical (NYSE: SEM) and ACADIA Pharmaceuticals (NASDAQ: ACAD)

Joanne WuenschCiti

Citi

―

Buy

―

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (Other OTC: SEMHF) and Dexcom (NASDAQ: DXCM)

Josh JenningsTD Cowen

TD Cowen

$100

Buy

17.59%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Dexcom (NASDAQ: DXCM), Perspective Therapeutics (NYSE MKT: CATX) and Codexis (NASDAQ: CDXS)

Travis SteedBank of America Securities

Bank of America Securities

$105

Buy

23.47%

Upside

Reiterated

06/22/25

Analysts Conflicted on These Healthcare Names: Cytek Biosciences (NASDAQ: CTKB), Dexcom (NASDAQ: DXCM) and Solid Biosciences (NASDAQ: SLDB)

Richard NewitterTruist Financial

Truist Financial

$102

Buy

19.94%

Upside

Initiated

06/16/25

Dexcom's Strong Growth Potential and Market Position Justify Buy Rating

Matthew O'BrienPiper Sandler

Piper Sandler

$90→$100

Buy

17.59%

Upside

Reiterated

06/11/25

Piper Sandler Sticks to Its Buy Rating for Dexcom (DXCM)

David RomanGoldman Sachs

Goldman Sachs

$86.67

Buy

1.92%

Upside

Initiated

05/30/25

Dexcom (DXCM) Initiated with a Buy at Goldman Sachs

Matthew TaylorJefferies

Jefferies

$105→$110

Buy

29.35%

Upside

Reiterated

05/29/25

Dexcom's Strategic Growth and Market Expansion Justifies Buy Rating

Shagun Singh ChadhaRBC Capital

RBC Capital

$100

Buy

17.59%

Upside

Reiterated

05/28/25

RBC Capital Sticks to Its Buy Rating for Dexcom (DXCM)

Jeff JohnsonRobert W. Baird

Robert W. Baird

$115→$105

Buy

23.47%

Upside

Reiterated

05/02/25

DexCom price target lowered to $105 from $115 at BairdDexCom price target lowered to $105 from $115 at Baird

Matt MiksicBarclays

Barclays

$90→$93

Hold

9.36%

Upside

Reiterated

05/02/25

Barclays Sticks to Their Hold Rating for Dexcom (DXCM)

Lee HambrightBernstein

Bernstein

$100→$88

Buy

3.48%

Upside

Reiterated

05/02/25

DexCom (DXCM) PT Lowered to $88 at Bernstein SocGen GroupBernstein SocGen Group analyst Lee Hambright lowered the price target on DexCom (NASDAQ: DXCM) to $88.00 (from $100.00) while maintaining an Outperform rating.

Mathew BlackmanStifel Nicolaus

Stifel Nicolaus

$100

Buy

17.59%

Upside

Reiterated

05/02/25

Dexcom (DXCM) Gets a Buy from Stifel Nicolaus

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

TipRanks AITipRanks

Not Ranked

TipRanks

$100

Buy

17.59%

Upside

Reiterated

06/25/25

Steven LichtmanOppenheimer

Oppenheimer

$95

Buy

11.71%

Upside

Reiterated

06/24/25

Oppenheimer Sticks to Its Buy Rating for Dexcom (DXCM)

Larry BiegelsenWells Fargo

Wells Fargo

$98

Buy

15.24%

Upside

Reiterated

06/24/25

Analysts' Opinions Are Mixed on These Healthcare Stocks: Dexcom (NASDAQ: DXCM), Select Medical (NYSE: SEM) and ACADIA Pharmaceuticals (NASDAQ: ACAD)

Joanne WuenschCiti

Citi

―

Buy

―

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (Other OTC: SEMHF) and Dexcom (NASDAQ: DXCM)

Josh JenningsTD Cowen

TD Cowen

$100

Buy

17.59%

Upside

Reiterated

06/23/25

Analysts Offer Insights on Healthcare Companies: Dexcom (NASDAQ: DXCM), Perspective Therapeutics (NYSE MKT: CATX) and Codexis (NASDAQ: CDXS)

Travis SteedBank of America Securities

Bank of America Securities

$105

Buy

23.47%

Upside

Reiterated

06/22/25

Analysts Conflicted on These Healthcare Names: Cytek Biosciences (NASDAQ: CTKB), Dexcom (NASDAQ: DXCM) and Solid Biosciences (NASDAQ: SLDB)

Richard NewitterTruist Financial

Truist Financial

$102

Buy

19.94%

Upside

Initiated

06/16/25

Dexcom's Strong Growth Potential and Market Position Justify Buy Rating

Matthew O'BrienPiper Sandler

Piper Sandler

$90→$100

Buy

17.59%

Upside

Reiterated

06/11/25

Piper Sandler Sticks to Its Buy Rating for Dexcom (DXCM)

David RomanGoldman Sachs

Goldman Sachs

$86.67

Buy

1.92%

Upside

Initiated

05/30/25

Dexcom (DXCM) Initiated with a Buy at Goldman Sachs

Matthew TaylorJefferies

Jefferies

$105→$110

Buy

29.35%

Upside

Reiterated

05/29/25

Dexcom's Strategic Growth and Market Expansion Justifies Buy Rating

Shagun Singh ChadhaRBC Capital

RBC Capital

$100

Buy

17.59%

Upside

Reiterated

05/28/25

RBC Capital Sticks to Its Buy Rating for Dexcom (DXCM)

Jeff JohnsonRobert W. Baird

Robert W. Baird

$115→$105

Buy

23.47%

Upside

Reiterated

05/02/25

DexCom price target lowered to $105 from $115 at BairdDexCom price target lowered to $105 from $115 at Baird

Matt MiksicBarclays

Barclays

$90→$93

Hold

9.36%

Upside

Reiterated

05/02/25

Barclays Sticks to Their Hold Rating for Dexcom (DXCM)

Lee HambrightBernstein

Bernstein

$100→$88

Buy

3.48%

Upside

Reiterated

05/02/25

Mathew BlackmanStifel Nicolaus

Stifel Nicolaus

$100

Buy

17.59%

Upside

Reiterated

05/02/25

Dexcom (DXCM) Gets a Buy from Stifel Nicolaus

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dexcom

1 Month

xxx

Success Rate

27/47 ratings generated profit

Average Return

+3.40%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 57.45% of your transactions generating a profit, with an average return of +3.40% per trade.

3 Months

xxx

Success Rate

21/30 ratings generated profit

Average Return

+4.43%

reiterated a xxx

rating 11 months ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 70.00% of your transactions generating a profit, with an average return of +4.43% per trade.

1 Year

Joanne WuenschCiti

Success Rate

31/38 ratings generated profit

Average Return

+33.69%

reiterated a buy rating 10 days ago

Copying Joanne Wuensch's trades and holding each position for 1 Year would result in 81.58% of your transactions generating a profit, with an average return of +33.69% per trade.

2 Years

xxx

Success Rate

36/47 ratings generated profit

Average Return

+89.99%

reiterated a xxx

rating 4 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 76.60% of your transactions generating a profit, with an average return of +89.99% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DXCM Analyst Recommendation Trends

Rating

Feb 25

Mar 25

Apr 25

May 25

Jun 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, DXCM has received 44 Buy Ratings, 2 Hold Ratings, and 0 Sell Ratings. DXCM average Analyst price target in the past 3 months is 99.04.

Each month's total comprises the sum of three months' worth of ratings.

DXCM Financial Forecast

DXCM Earnings Forecast

Next quarter’s earnings estimate for DXCM is $0.44 with a range of $0.40 to $0.49. The previous quarter’s EPS was $0.32. DXCM beat its EPS estimate 50.00% of the time in the past 12 months, while its overall industry beat the EPS estimate 58.14% of the time in the same period. In the last calendar year DXCM has Outperformed its overall industry.

DXCM Sales Forecast

Next quarter’s sales forecast for DXCM is $1.12B with a range of $1.12B to $1.15B. The previous quarter’s sales results were $1.04B. DXCM beat its sales estimates 75.00% of the time in past 12 months, while its overall industry beat sales estimates 47.46% of the time in the same period. In the last calendar year DXCM has Outperformed its overall industry.

DXCM Stock Forecast FAQ

What is DXCM’s average 12-month price target, according to analysts?

Based on analyst ratings, Dexcom’s 12-month average price target is 99.04.

What is DXCM’s upside potential, based on the analysts’ average price target?

Dexcom has 16.46% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is DXCM a Buy, Sell or Hold?

Dexcom has a consensus rating of Strong Buy which is based on 19 buy ratings, 1 hold ratings and 0 sell ratings.

What is Dexcom’s price target?

The average price target for Dexcom is 99.04. This is based on 20 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $110.00 ,the lowest forecast is $85.00. The average price target represents 16.46% Increase from the current price of $85.04.

What do analysts say about Dexcom?

Dexcom’s analyst rating consensus is a Strong Buy. This is based on the ratings of 20 Wall Streets Analysts.

How can I buy shares of DXCM?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Dexcom (DXCM) Stock Forecast & Price Target

DXCM Analyst Ratings

DXCM Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Dexcom

DXCM Analyst Recommendation Trends

DXCM Financial Forecast

DXCM Earnings Forecast

DXCM Sales Forecast

DXCM Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts